No Data
No Data
友芝友生物-B:2023年度報告
Tomoshiba Bio-B (02496) announced annual results. Shareholders' losses of 192 million yuan increased 1.5% year-on-year
Tomoshibayu Bio-B (02496) announced its annual results for the year ended December 31, 2023. The group...
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Tomoshibayu Bio-B (02496): Phase III clinical trial of the bispecific antibody M701 malignant ascites completed the first patient enrollment
According to Zhitong Finance App, Youzhiyou Bio-B (02496) announced that M701, an investigational bispecific antibody (BsAb) drug that targets both epithelial cell adhesion molecule (epCAM) and differentiation cluster 3 (CD3) independently developed by the company, recently completed the first patient enrollment in a critical phase III registered clinical trial (malignant ascites study). The purpose of the malignant ascites study was to evaluate the efficacy and safety of peritoneal perfusion M701 compared with abdominal puncture drainage in patients with malignant ascites caused by advanced solid epithelial tumors. If successful, malignant ascites research will be used to support M701 in China
Wuhan Yzy Biopharma Enrolls First Participant in Cancer Drug's Phase II Clinical Trial
Wuhan Yzy Biopharma (HKG:2496) enrolled the first patient in the Phase II clinical trial for its lung cancer drug, according to a Tuesday Hong Kong bourse filing. The drug targets both the cancer and
Tomoshibayu Bio-B (02496): Phase II clinical trial of the bispecific antibody M701 malignant pleural effusion completed the first patient enrollment
Tomoshibayu Bio-B (02496) announced that the company's self-developed epithelial cell adhesion molecule (epCAM)...
No Data